Lincoln Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2025.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals held its 31st AGM on September 30, 2025, via video conferencing, attended by 85 shareholders. The board recommended a dividend of Rs. 1.80 per equity share (18%) for FY 2024-25. Auditors' and Secretarial Audit Reports contained no qualifications or adverse remarks. Shareholders approved the adoption of audited standalone and consolidated financial statements for FY ended March 31, 2025, and the re-appointment of two directors retiring by rotation. The meeting also considered the re-appointment of Mr. Mahendra G. Patel as Managing Director for 5 years from October 1, 2025, and re-appointments of three Whole Time Directors for 5-year terms. A new secretarial auditor, M/s. Ankit Sethi & Associates, was proposed for a 5-year term. Voting results from remote e-voting and AGM e-voting are awaited within 2 working days.
The Rs. 1.80 per share dividend rewards shareholders at an 18% payout rate. Clean audit reports and continuity in leadership with multiple director re-appointments signal operational stability. Investors should watch for the formal voting results to confirm approval of all resolutions.